Page 1

May 12 , 2021 Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results NEW YORK , May 12 , 2021 / PRNewswire / -- Relmada Therapeutics , Inc. ( Nasdaq : RLMD ) , a late - stage biotechnology company addressing diseases of the central nervous system ( CNS ) , today provided a corporate update and announced financial results for the first quarter ended March 31 , 2021 . B Relmada THERAPEUTICS " We continue to advance the development of our lead product candidate , REL - 1017 , for the treatment of major depressive disorder ( MDD ) , " said Sergio Traversa , Relmada's Chief Executive Officer . " The RELIANCE Clinical Development Program is underway . The first of two pivotal Phase 3 trials , RELIANCE I , continues to enroll as planned and we recently began enrolling participants in the second study , RELIANCE II . The long - term , open - label safety study , RELIANCE - OLS , is also actively enrolling participants from the pivotal studies as well as new participants . Importantly , we expect multiple key clinical data over the next several quarters . We also continue to build on the clinical evidence in support of REL - 1017 through the presentation of data at scientific meetings , particularly through learnings regarding the mechanism of action that underlies the clinical profile of REL - 1017 . " Recent Corporate Highlights • Continued enrollment of participants in the first pivotal Phase 3 clinical trial , RELIANCE I , for REL - 1017 as an adjunctive treatment for MDD . • Initiation of RELIANCE II , the second pivotal Phase 3 clinical trial for REL - 1017 as an adjunctive treatment for MDD . • Presentation of nine posters highlighting preclinical and clinical data for REL - 1017 at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021 , the 2021 Society of Biological Psychiatry Annual Meeting and the American Psychiatric Association Annual Meeting 2021 . Upcoming Anticipated Milestones for REL - 1017 • 1H21 – Start of the monotherapy MDD trial • 2Q21 - Completion of the human abuse potential study with oxycodone • 2H21 - Completion of the human abuse potential study with ketamine • 4Q21 - Completion of the monotherapy MDD trial • 1H22 - Completion of RELIANCE I and RELIANCE II adjunctive MDD trials